B02

Key Product Details

Product Description

B02 is a RAD51 recombinase inhibitor, exhibiting selectivity for human RAD51 over the E.coli homologue RecA (IC₅₀ values are 27.4 μM and >250 μM, respectively). Inhibits homologous recombination and increases cellular sensitivity to DNA damage in vitro. Enhances the therapeutic effect of cisplatin (Cat. No. 2251) on tumor cells in vivo.

Product Specifications for B02

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Solubility

Preparing Stock Solutions for B02

The following data is based on the product molecular weight 339.40.

Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which all affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:

1 Recalculate

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	2.95 mL	14.73 mL	29.46 mL
5 mM	0.59 mL	2.95 mL	5.89 mL
10 mM	0.29 mL	1.47 mL	2.95 mL
50 mM	0.06 mL	0.29 mL	0.59 mL

Calculators

Background References

References are publications that support the biological activity of the product. See our Citations tab to view 10 publications citing the usage of this product.

• Huang and Mazin A small molecule inhibitor of human RAD51 potentiates breast cancer cell killing by therapeuticagents in mouse xenografts. PLoS One 2014 PMID: 24971740
• Huang Inhibition of homologous recombination in human cells by targeting RAD51 recombinase. J.Med.Chem. 2012 PMID: 22380680
• Alagpulinsa A small-molecule inhibitor of RAD51 reduces homologous recombination and sensitizes multiple myeloma cells to dox. Front.Oncol. 2014 PMID: 25401086
• Huang Identification of specific inhibitors of human RAD51 recombinase using high-throughputscreening. ACS Chem.Biol. 2011 PMID: 21428443

Product Documents for B02